Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.
Di Lorenzo G, Bracarda S, Gasparro D, Gernone A, Messina C, Zagonel V, Puglia L, Bosso D, Dondi D, Sonpavde G, Lucarelli G, De Placido S, Buonerba C. Di Lorenzo G, et al. Among authors: sonpavde g. Medicine (Baltimore). 2016 Jan;95(2):e2299. doi: 10.1097/MD.0000000000002299. Medicine (Baltimore). 2016. PMID: 26765406 Free PMC article. Clinical Trial.
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S. Di Lorenzo G, et al. Among authors: sonpavde g. BJU Int. 2012 Dec;110(11 Pt B):E661-6. doi: 10.1111/j.1464-410X.2012.11453.x. Epub 2012 Sep 10. BJU Int. 2012. PMID: 22958571
Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G, DʼAniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S. Di Lorenzo G, et al. Among authors: sonpavde g. Anticancer Drugs. 2013 Jan;24(1):84-9. doi: 10.1097/CAD.0b013e32835a56bc. Anticancer Drugs. 2013. PMID: 23044721
Penile cancer: current therapy and future directions.
Sonpavde G, Pagliaro LC, Buonerba C, Dorff TB, Lee RJ, Di Lorenzo G. Sonpavde G, et al. Ann Oncol. 2013 May;24(5):1179-89. doi: 10.1093/annonc/mds635. Epub 2013 Jan 4. Ann Oncol. 2013. PMID: 23293117 Free PMC article. Review.
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: sonpavde g. Future Oncol. 2013 Jun;9(6):889-97. doi: 10.2217/fon.13.39. Future Oncol. 2013. PMID: 23718309
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Pond GR, et al. Among authors: sonpavde g. Clin Genitourin Cancer. 2013 Dec;11(4):495-500. doi: 10.1016/j.clgc.2013.04.025. Epub 2013 Jun 22. Clin Genitourin Cancer. 2013. PMID: 23800847
501 results